Evidence map›Paper›PMID 40592930›Full record

ArticleNature communications2025

An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy.

Yining Zhu, Zhi-Cheng Yao, Shuyi Li, Jingyao Ma, Christine Wei, Di Yu, Jessica L Stelzel, Bobby Y X Ni, Yang Miao, Kyra Van Batavia and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Unlock the sustained therapeutic efficacy of mRNA.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Yining Zhu *Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-7178-0097
Zhi-Cheng Yao *Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Shuyi Li *Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Jingyao MaInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Christine WeiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0009-0005-0831-6813
Di YuDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jessica L StelzelDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5644-9240
Bobby Y X NiDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Yang MiaoDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Kyra Van BataviaDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.ORCID http://orcid.org/0009-0006-5419-9221
Xiaoya LuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Jinghan LinInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Yifan DaiDepartment of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-7897-5228
Jiayuan KongInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Ruochen ShenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9967-4758
Kailei D GoodierInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Xiang LiuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Leonardo ChengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ivan VuongDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gregory P HowardDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Natalie K LivingstonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Joseph ChoyInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6282-9437
Jonathan P SchneckInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5346-2776
Joshua C DoloffDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4323-3264
Sashank K ReddyDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
John W HickeyDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Hai-Quan MaoDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hmao@jhu.edu.ORCID http://orcid.org/0000-0002-4262-9988

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JONATHAN P SCHNECK · 2019 to 2026
$11.5M
Development of an oral liver-targeted prime-and-trap malaria vaccineU01AI155313 · NIAID · UNIVERSITY OF WASHINGTON · PI MURPHY, SEAN C · 2021 to 2025
$4.1M
Engineered Lipid Nanoparticles and Microgel Matrix to Program Th1/Th2 Immune ResponseR01CA293906 · NCI · JOHNS HOPKINS UNIVERSITY · PI Hai-Quan Mao · 2025 to 2026
$1.2M
NCI NIH HHS R01 CA293906NIAID NIH HHS U01 AI155313NIBIB NIH HHS P41 EB028239U.S. Department of Health & Human Services | National Institutes of Health (NIH) P41EB028239U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA293906U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U01AI155313
6 · The paper itself

Abstract

Hydrogel materials have emerged as versatile platforms for various biomedical applications. Notably, the engineered nanofiber-hydrogel composite (NHC) has proven effective in mimicking the soft tissue extracellular matrix, facilitating substantial recruitment of host immune cells and the formation of a local immunostimulatory microenvironment. Leveraging this feature, here we report an mRNA lipid nanoparticle (LNP)-incorporated NHC microgel matrix, termed LiNx, by incorporating LNPs loaded with mRNA encoding tumour antigens. Harnessing the high transfection efficiency of LNPs in antigen-presenting cells, LiNx demonstrates substantial levels of immune cell recruitment, antigen expression and presentation, and cellular interaction. These attributes collectively create an immunostimulating microenvironment and yield a potent immune response with a single dose at a level comparable to the conventional three-dose LNP immunization protocol. Further investigation reveals that the LiNx generates not only high levels of Th1 and Th2 responses, but also a distinct Type 17 T helper cell response critical for bolstering antitumour efficacy. Our findings elucidate the mechanism underlying LiNx's role in potentiating antigen-specific immune responses, presenting a strategy for cancer immunotherapy.

Indexed as

HydrogelsImmunotherapyLipidsNanofibersNanoparticlesNeoplasmsRNA, MessengerAnimalsAntigens, NeoplasmCell Line, TumorFemaleHumansLiposomesMiceMice, Inbred C57BLTumor MicroenvironmentAntigens, NeoplasmHydrogelsLipid NanoparticlesLipidsLiposomesRNA, Messenger

Identifiers

PMID40592930
PMCPMC12217393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.